1. Home
  2. VVX vs XERS Comparison

VVX vs XERS Comparison

Compare VVX & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo V2X Inc.

VVX

V2X Inc.

N/A

Current Price

$80.27

Market Cap

2.2B

ML Signal

N/A

XERS

Xeris Biopharma Holdings Inc.

N/A

Current Price

$16.73

Market Cap

1.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VVX
XERS
Founded
2014
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.8B
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
VVX
XERS
Price
$80.27
$16.73
Analyst Decision
Buy
Strong Buy
Analyst Count
12
7
Target Price
★ $90.27
$17.29
AVG Volume (30 Days)
324.3K
★ 3.2M
Earning Date
11-02-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 126.85
100.00
EPS
★ 2.42
N/A
Revenue
★ $4,480,038,000.00
$49,590,000.00
Revenue This Year
$12.52
$37.58
Revenue Next Year
$4.83
$31.16
P/E Ratio
$33.58
★ N/A
Revenue Growth
3.65
★ 142.67
52 Week Low
$50.89
$5.25
52 Week High
$93.98
$16.88

Technical Indicators

Market Signals
Indicator
VVX
XERS
Relative Strength Index (RSI) 57.03 82.90
Support Level $65.25 $5.90
Resistance Level $84.39 N/A
Average True Range (ATR) 3.72 0.66
MACD 0.32 0.56
Stochastic Oscillator 66.79 93.75

Price Performance

Historical Comparison
VVX
XERS

About VVX V2X Inc.

V2X Inc is a U.S.-based company that provides services to the U.S. government. It operates as one segment and offers facility and logistics services and information technology mission support and engineering and digital integration services. The information technology and network communications capabilities consist of communications systems operations and maintenance, management and service support, systems installation and activation, system-of-systems engineering and software development, and mission support for the department of defense. The facility and logistics service include airfield management, ammunition management, civil engineering, communications, emergency services, life support activities, public works, security, transportation operations, and others.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Share on Social Networks: